{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"464","value":"483"},{"groupId":"OG001","spread":"2085","value":"1472"},{"groupId":"OG002","spread":"3718","value":"1614"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"Maximum T cell expansion was defined as maximum observed plasma concentration (Cmax) after a single Infusion of JNJ-68284528.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 milligrams per meter square (mg/m\\^2) intravenous (IV) infusion and fludarabine 30 mg/m\\^2 as IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received target dose of JNJ-68284528 0.75\\*10\\^6 chimeric antigen receptor T (CAR-T) cells per kilogram (cells/kg) (range: 0.5-1.0\\*10\\^6 CAR-positive viable cells/kg) as IV infusion.","id":"OG000","title":"Phase 1b (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG001","title":"Phase 2 (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received RP2D dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG002","title":"Phase 2 (Japan Population)"}],"paramType":"MEAN","populationDescription":"mITT analysis set included all participants who received a JNJ-68284528 infusion at the targeted RP2D dose level.","reportingStatus":"POSTED","timeFrame":"Pre and post dose on Day 1 and Days 2, 3, 7, 10, 14, 21, 28, 42, 56, 78, 100, then every 4 weeks up to 1 year, and at the time of progressive disease or at study completion for participants without progressive disease (up to approximately 2.5 years)","title":"Phase 1b and Phase 2: Maximum T Cell Expansion After a Single Infusion of JNJ-68284528","type":"SECONDARY","unitOfMeasure":"Cells per microliter"}